Congress has found little to agree on when it comes to health care, but lawmakers from both parties appear to be warming up to ideas for reining in drug prices.
While soaring prescription costs have drawn fire from across the political spectrum, action has been scant. There are signs however that a consensus is forming on Capitol Hill on how to curtail tactics that shield blockbuster medicines from competition.
Among industry practices lawmakers are taking a critical look at are paying competitors to keep new generics on the sidelines and making minor tweaks to drugs to extend their patent life. Safety programs that keep rivals from accessing a medicine, effectively blocking generic versions by making drugs harder to copy, are also drawing scrutiny.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
